These are publications from work undertaken by Frontier Science (Scotland).

A Goldhirsch;  RD Gelber; M Piccart-Gebhart; E. de Azambuja; M Procter; T M Suter; C Jackisch; H A Weber; D Heinzmann; L D Lago; E McFadden; M Dowsett; M Untch; L Gianni; R Bell; A Vindevoghel; M Andersson; C Köhne; D Cameron;  2013

2 Years Versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): an Open-Label, Randomised Controlled Trial

The Lancet,  Volume 382, Issue 9897, Pages 1021-1028, doi: 10.1016/S0140-6736(13)61094-6

O Metzger-Filho;  M Procter; E. de Azambuja; B Leyland-Jones; RD Gelber; M Dowsett; S Loi; K S Saini; D Cameron; M Untch; I Smith; L Gianni; J Baselga; C Jackisch; R Bell; C Sotiriou; G Viale; M Piccart-Gebhart;  2013

Magnitude of Trastuzumab benefit in patients with HER2 positive, invasive lobular breast carcinoma: results from the HERA trial

Journal of Clinical Oncology,  Volume 31, Issue 16, Pages 1954-1960, doi: 10.1200/JCO.2012.46.2440

L Gianni;  U Dafni; RD Gelber; E. de Azambuja; S Muehlbauer; A Goldhirsch; M Untch; I Smith; J Baselga; C Jackisch; D Cameron; M Mano; J Luiz Pedrini; A Veronesi; C Mendiola; A Pluzanska; V Semiglazov; E Vrdoljak; M J Eckart; Z Shen; G Skiadopoulos; M Procter; KI Pritchard; R Bell;  2011

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow up of randomized controlled trail

The Lancet,  Volume 12, Issue 3, Pages 236-244, doi: 10.1016/S1470-2045(11)70033-X

M Procter;  T M Suter; E. de Azambuja; U Dafni; V Van Dooren; S Muehlbauer; M Angel Climent; E Rechberger; W Tsang-Wu Liu; M Toi; R C Coombes; D Dodwell; O Pagani; J Madrid; M Hall; S Chen; C Focan; M Muscholl; D J van Veldhuisen; M Piccart-Gebhart;  2010

Longer term assessment of trastuzumab for 1 year after adjuvant chemotherapy

Journal of Clinical Oncology,  Volume 28, Issue 21, Pages 3422-3428, doi: 10.1200/JCO.2009.26.0463

M Dowsett;  M Procter; M McCaskill-Stevens; M E de Azambuja; U Dafni;  2009

Disease free survival according to the degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year trastuzumab: the HERA trial

Journal of Clinical Oncology,  Volume 27, Issue 18, Pages 2962-2969, doi: 10.1200/JCO.2008.19.7939

M Untch;  RD Gelber; C Jackisch; M Procter; J Baselga; R Bell; D Cameron; M Bari; I Smith; B Leyland-Jones; E. de Azambuja; R Khasanov; F Feng-yi; C Constantin; J Mayordomo; C H Su; S Y Yu; E Senkus-Konefka; A Lluch; P Wermuth; C Price;  2008

Estimating the Magnitude of Trastuzumab effects within patient subgroups in the HERA trial

Annals of Oncology,  Volume 19, Issue 6, Pages 1090-1096, doi: 10.1093/annonc/mdn005

T M Suter;  M Procter; D J van Veldhuisen; M Muscholl; J Bergh; C Carlomagno; T Perren; R Passalacqua; C Bighin; J G M Klijn; F Ageev; E Hitre; J Groetz; H Iwata; M Knap; M Gnant; S Muehlbauer; A Spence; RD Gelber; M Piccart-Gebhart;  2007

Trastuzumab-Associated cardiac adverse effects in the Herceptin Adjuvant trial

Journal of Clinical Oncology,  Volume 25, Pages 3859-3865, doi:10.1200/JCO.2006.09.1611

I Smith;  M Procter; RD Gelber; S Guillaume; A Feyereislova; M Dowsett; A Goldhirsch; M Untch; G Mariani; J Baselga; M Kaufmann; D Cameron; R Bell; J Bergh; A Wardley; N Harbeck; R I Lopez-Sanchez; P Mallmann; K Gelmon; N Wilcken; E Wist; P Sánchez Rovira; R Coleman;  2007

2 Year follow up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial

The Lancet,  Volume 369, Issue 9555, Pages 29-36, doi:10.1016/S0140-6736(07)60028-2

E. de Azambuja;  M Procter; D J van Veldhuisen; D Agbor-Tarh; O Metzger-Filho; J Steinseifer; M Untch; I Smith; L Gianni; J Baselga; C Jackisch; D Cameron; R Bell; B Leyland-Jones; M Dowsett; RD Gelber; M Piccart-Gebhart; T M Suter;  2014

Trastuzumab-associated cardiac events at 8 years of median follow up in the herceptin adjuvant trial (BIG 1-01)

Journal of Clinical Oncology,  Volume 32, Issue 20, Pages 2159-2165, doi:10.1200/JCO.2013.53.9288

A Sonnenblick;  D Agbor-Tarh; I Bradbury; S Di Cosimo; J A Zujewski; H A Azim Jr; J Judith; M Andersson; T Cufer; S Simon; P Salman; M Toi; L Harris; J Gralow; A Moreno-Aspitia; M. Piccart; E. de Azambuja; K Macoon;  2016

The Impact of Diabetes and Metformin Usage on the Outcome of HER2 Positive Primary Breast Cancer Patients. Analysis from the ALTTO Phase III Randomized Trial

European Journal of Cancer,  Volume 57, Issue 2, Pages S155-S167, doi: 10.1200/JCO.2016.69.7722